General
AstraZeneca COVID-19 vaccine faces regulatory hurdles as Novavax releases both ‘encouraging’ and ‘concerning’ results
Experts say the problems associated with “first-generation” COVID-19 vaccines are being exposed, as one European regulatory body questions the lack of data supplied for the Oxford-AstraZeneca vaccine and recommending against its use for the elderly.
Key points:
- European regulatory bodies are concerned over the lack of data for the elderly during trials of the Oxford-AstraZeneca vaccine
- The TGA, described as “the best regulator in the world” by the Health Minister, is expected to make a decision in February
- It comes as Novavax, the third vaccine the Australian Government has committed to purchasing, released “encouraging” interim results
On Friday, Germany’s vaccine committee recommended the Oxford-AstraZeneca vaccine — of which…
Continue Reading
-
Noosa News22 hours agoInside the $5.4 million Clayfield home where CEO Greg Josephson was allegedly stabbed to death
-
Business23 hours agoHow you could turn $10k into $100k with ASX shares
-
Noosa News24 hours agoPolice charge teen with alleged murder of Universal Store co-founder
-
Noosa News24 hours agoIllegal explosives and firearms allegedly uncovered during DV-related raid at Walkerston in Mackay